Eli Lilly (LLY.US) is scheduled to release its first-quarter 2026 financial results before the U.S. market opens on April 30. Despite a stock price decline of over 19% year-to-date, Wall Street analysts generally believe the company's dominant position in the weight-loss drug market remains secure. The recently launched oral weight-loss drug Foundayo, along with emerging pipelines such as gene editing therapies, are becoming key factors that will determine its future valuation.
Strong earnings are anticipated, yet the market's focus is on future catalysts. Market consensus expects Eli Lilly to report a quarter of significant revenue growth. Compiled data indicates that Lilly's Q1 adjusted earnings per share are projected to be $6.85, with revenue surging 40.3% year-over-year to $17.86 billion. Over the past three months, revenue estimates have been revised upwards eight times versus only one downward revision, reflecting strong confidence in its revenue prospects.
Lilly's weight-loss business remains robust. Leveraging Zepbound, one of the market's most effective and best-selling weight-loss drugs, and Foundayo, one of the first oral GLP-1 medications, analysts project that Lilly's total GLP-1 product sales will grow at an average annual rate of 14% to approximately $45 billion by 2031. Morningstar analyst Karen Andersen noted that Lilly's 2026 growth is heavily dependent on the continued expansion of Mounjaro and Zepbound, its drugs for diabetes and obesity. Overall, the company's mid-point revenue growth guidance for 2026 is 25%.
However, the quarterly report itself might not be the primary focus. Analysts are paying closer attention to the subsequent management conference call.
Foundayo's debut attracts attention but may not be the sole highlight. Since Lilly's new oral weight-loss drug Foundayo was approved on April 1st and began shipping on April 6th, its impact will not be reflected in the Q1 report. Commentary from management regarding early prescription trends and market acceptance will provide the first critical insight for assessing its competitive prospects. Morningstar already forecasts $1.7 billion in sales for the drug this year and is optimistic that its production advantages as a small-molecule drug will lead to faster growth internationally than in the U.S.
Questions surrounding Foundayo center on its ability to gain a foothold in the already competitive oral weight-loss drug market. Seeking Alpha analyst Stephen Ayers pointed out that if Lilly can reaffirm its full-year 2026 revenue guidance, it could be a positive signal that Foundayo is on track. Conversely, if the guidance range is narrowed towards the lower end, it might indicate pricing pressure or weaker-than-expected market uptake for Foundayo.
Some perspectives suggest that investor focus might be overly concentrated on the intense competition within the GLP-1 space, potentially overlooking the next wave of innovation Lilly is developing. Leerink Partners analyst David Risinger stated that Lilly's new drug in development, the amylin analog eloralintide, has the potential to be a "game-changer" that breaks the current competitive stalemate. This drug offers a new option for patients intolerant to or experiencing diminished response from existing GLP-1 medications. Early data suggests that combining it with tirzepatide (the active ingredient in Mounjaro and Zepbound) could yield superior weight loss efficacy and tolerability. Risinger expects this combination therapy to advance to Phase III clinical trials in the second half of this year, potentially building a new, formidable competitive barrier for Lilly.
A notable "second growth curve" beyond weight-loss drugs is also taking shape. Lilly is actively utilizing the substantial cash flow generated by its weight-loss drugs to invest in its long-term future. Earlier this month, the company announced the acquisition of gene therapy company Kelonia Therapeutics for up to $7 billion, marking another move in 2024 within the in vivo CAR-T cell therapy space. This technology aims to provide a cheaper, more convenient, and potentially more effective method for treating cancer and even autoimmune diseases. While Kelonia is not yet revenue-generating, its therapy for multiple myeloma has entered Phase I clinical trials.
Analysts view this move positively, believing it helps bolster Lilly's oncology pipeline and achieve long-term growth diversification, reducing reliance solely on the GP-1 business. BMO analyst Evan Siegerman commented, "We view this potential transaction positively as it adds a complementary in vivo therapeutic approach that could broaden Lilly's oncology footprint." UBS analyst Michael Yee added that the acquisition helps Lilly "diversify its pipeline and lay the foundation for long-term growth beyond the GLP-1 product line." Statistics show global oncology treatment spending reached $256 billion in 2025 and is projected to approach $700 billion by 2034. For Lilly, which has annual revenue expectations exceeding $80 billion, capturing a share of the vast oncology market could provide substantial additional growth.
Pricing pressures coexist with incremental opportunities. Nonetheless, Lilly's growth faces multiple uncertainties. The company's core growth engines, Mounjaro and Zepbound, are confronting pricing challenges. Morningstar analysts noted that despite strong volume growth, their prices in the U.S. private insurance and cash-pay markets could face continued erosion this year. Furthermore, pricing pressures in China and the U.S. "Most Favored Nation" pricing clause may also impact international sales of other key drugs.
However, changing policy environments also present benefits for Lilly. A pilot program from the U.S. Centers for Medicare & Medicaid Services, set to begin in July, is expected to significantly expand coverage for Zepbound and Foundayo among Medicare beneficiaries, capping monthly out-of-pocket costs for GLP-1 drugs at $50. Morgan Stanley described this as a "landmark opening" for Medicare coverage of weight-loss drugs, while Mizuho analysts believe it could drive over 20% upside for the stock price.
Comments